Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Dec;30(13):8166-8167.
doi: 10.1245/s10434-023-13981-8. Epub 2023 Jul 21.

ASO Author Reflections: Which HIPEC Regimens Should be Used in Patients with Epithelial Ovarian Cancer? In the Clinic and in Randomized Trials

Aditi Bhatt  1 , Olivier Glehen  2 , Naoual Bakrin  2 , Donal Brennan  3 , Willemien Van Driel  4
Affiliations
Comment

ASO Author Reflections: Which HIPEC Regimens Should be Used in Patients with Epithelial Ovarian Cancer? In the Clinic and in Randomized Trials

Aditi Bhatt et al. Ann Surg Oncol. 2023 Dec.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Bhatt A, Glehen O. Hyperthermic intraperitoneal chemotherapy in the treatment armamentarium of epithelial ovarian cancer: time to end the dichotomy. Visc Med. 2022;38(2):109–19. https://doi.org/10.1159/000521239 . (PMID: 35614893; PMCID: PMC9082174). - DOI - PubMed - PMC
    1. Lim MC, Chang SJ, Park B, Yoo HJ, Yoo CW, Nam BH, Park SY. HIPEC for ovarian cancer collaborators. Survival after hyperthermic intraperitoneal chemotherapy and primary or interval cytoreductive surgery in ovarian cancer: a randomized clinical trial. JAMA Surg. 2022;157(5):374–83. https://doi.org/10.1001/jamasurg.2022.0143 . (PMID: 35262624; PMCID: PMC8908225). - DOI - PubMed - PMC
    1. Bhatt A, Glehen O, Zivanovic O, Brennan D, Nadeau C, Van Driel W, Bakrin N. The 2022 PSOGI international consensus on HIPEC regimens for peritoneal malignancies: epithelial ovarian cancer. Ann Surg Oncol. 2023. https://doi.org/10.1245/s10434-023-13932-3 . - DOI - PubMed
    1. Kim JH, Chun SY, Lee DE, Woo YH, Chang SJ, Park SY, Chang YJ, Lim MC. Cost-effectiveness of hyperthermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III-IV ovarian cancer from a randomized controlled phase III trial in Korea (KOV-HIPEC-01). Gynecol Oncol. 2023;170:19–24. https://doi.org/10.1016/j.ygyno.2022.12.021 . (Epub 2023 Jan 4 PMID: 36608383). - DOI - PubMed
    1. You B, Purdy C, Copeland LJ, Swisher EM, Bookman MA, Fleming G, Coleman R, et al. Identification of patients with ovarian cancer experiencing the highest benefit from bevacizumab in the first-line setting on the basis of their tumor-intrinsic chemosensitivity (KELIM): the GOG-0218 validation study. J Clin Oncol. 2022;40(34):3965–74. https://doi.org/10.1200/JCO.22.01207 . (PMID: 36252167; PMCID: PMC9746742). - DOI - PubMed - PMC

LinkOut - more resources